As­traZeneca says its $200M cash bet on Io­n­is’ AT­TR drug is pay­ing off — with PhI­II da­ta set­ting up FDA fil­ing

When As­traZeneca wa­gered $200 mil­lion in cash up­front to bring in Io­n­is’ an­ti­sense can­di­date for hered­i­tary transthyretin-me­di­at­ed amy­loid polyneu­ropa­thy (AT­TRv-PN), it was not shy about …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER